A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

November 22, 2022

Study Completion Date

January 3, 2023

Conditions
AnxietyNeurastheniaAdjustment Disorders
Interventions
DRUG

Ranquilon

Two 1 mg tablets 3 times per day for 28 days

DRUG

Placebo

Two tablets 3 times per day for 28 days

Trial Locations (10)

191119

"Limited Liability Company Research Center Eco-Security", Saint Petersburg

194000

EosMED JSC, Saint Petersburg

194156

"Limited Liability Company Energy of Health", Saint Petersburg

"LLC Aurora MedFort", Saint Petersburg

196143

"Limited Liability Company Research Center Eco-Safety", Saint Petersburg

199406

"Limited Liability Company Meili", Saint Petersburg

410038

Saratov City Psychoneurological Dispensary, Saratov

413090

Engels Psychiatric Hospital State Health Care Institution of the Ministry of Health of the Saratov Region, Engel's

603155

"State Budgetary Health Institution of Nizhny Novgorod Oblast Clinical Psychiatric Hospital No. 1 of Nizhny Novgorod. Nizhny Novgorod", Nizhny Novgorod

614070

Professors' Clinic LLC., Perm

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY